JPH0214326B2 - - Google Patents

Info

Publication number
JPH0214326B2
JPH0214326B2 JP56056933A JP5693381A JPH0214326B2 JP H0214326 B2 JPH0214326 B2 JP H0214326B2 JP 56056933 A JP56056933 A JP 56056933A JP 5693381 A JP5693381 A JP 5693381A JP H0214326 B2 JPH0214326 B2 JP H0214326B2
Authority
JP
Japan
Prior art keywords
weight
feed
parts
macrotetrolide
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56056933A
Other languages
Japanese (ja)
Other versions
JPS57171919A (en
Inventor
Koji Sakamoto
Akikazu Matsuo
Takeshi Asano
Isao Koya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Nippon Kayaku Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Nippon Kayaku Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP56056933A priority Critical patent/JPS57171919A/en
Publication of JPS57171919A publication Critical patent/JPS57171919A/en
Publication of JPH0214326B2 publication Critical patent/JPH0214326B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Fodder In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はマクロテトロライド系抗生物質及び非
イオン界面活性剤を含有する家畜・家禽用抗菌・
抗原虫剤及び生長促進剤に関する。 近年、マクロテトロライド系抗生物質に家畜・
家禽の成長促進、飼料効率の向上、疾病の予防及
び治療などの効果のあるとが見出され、その実用
化が期待されている。 しかし、マクロテトロライド系抗生物質のin―
vitvoにおける効果とin―vivoにおける効果が必
ずしも一致せず、in―vivoにおける効果の発明が
充分でなく、そのため、投与量を増やさなければ
ならないという問題がある。 そこで、本発明者らはマクロテトロライド系抗
生物質の効果がin―vivoにおいても充分発揮しう
るようにするため、種々検討をおこなつた結果、
マクロテトロライド系抗生物質及び非イオン界面
活性剤を含有する組成物を家畜・家禽に経口的に
投与することにより、その効果が充分発揮され、
投与量を減らしても発育促進効果などが充分発現
されることを見出した。 本発明は上記知見により完成されたものであ
る。 本発明で使用されるマクロテトロライド系抗生
物質としては例えばノナクチン、モナクチン、ジ
ナクチン、トリナクチン、テトラナクチンなどが
あげられる。これらは混合して使用してもよい。 非イオン界面活性剤としては例えばグリセリン
脂肪酸エステル、シヨ糖脂肪酸エステル、プロピ
レングリコール脂肪酸エステル、ポリオキシエチ
レン脂肪酸エステル、ポリオキシエチレングリセ
リン脂肪酸エステル、ポリオキシエチレンソルビ
タン脂肪酸エステル、ポリオキシエチレン硬化ヒ
マシ油誘導体などがあげられるが、ポリオキシエ
チレン脂肪酸エステル、ポリオキシエチレングリ
セリン脂肪酸エステル、ポリオキシエチレンソル
ビタン脂肪酸エステル、ポリオキシエチレン硬化
ヒマシ油誘導体などのポリオキシエチレン系の非
イオン界面活性剤が好ましい。これらは混合して
使用してもよい。 マクロテトロライド系抗生物質と非イオン界面
活性剤との使用比率は前者1重量部に対し、後者
1重量部以上、好ましくは1―1000重量部、さら
に好ましくは1〜100重量部がよい。 本発明の製剤はマクロテトロライド系抗生物質
及び非イオン界面活性剤とを含有しているもので
あれば特に制限はないが、例えば上記2者を混合
しただけのもの、上記2者と賦形剤とを混合した
製剤又は上記2者を含有する飼料などがあげられ
る。 賦形剤としては例えば小麦粗粉、小麦スソ粉、
大豆粗粉、大豆油かす、コーンスターチ、コーン
ミール、脱脂米糠、ふすま、甘薯でんぷん、乳
糖、酵母、油脂、炭酸カルシウム、タルク、木質
粉末、カリオン、白亜珪藻土、水、生理的食塩水
等があげられる。 飼料としては市販されている家畜・家禽用飼料
であればよく、例えばトウモロコシ、マイロなど
の穀類、大豆粕などの食用油粕、フスマ、米糠な
どの糟糠類、コーングルテンミール、でんぷん
粕、しよう油粕、糖蜜などの製造粕類、肉骨粉、
魚粉、ホエー、脱脂粉乳、血粉、フエザーミー
ル、動物性油脂などの動物質類、などの飼料原料
を適当な割合に混合したもの、又はさらにミネラ
ル、ビタミン、アミノ酸などの飼料添加物を加え
て作つた飼料でもよい。 本発明の製剤を製造するにはマクロテトロライ
ド系抗生物質を揮発しやすい有機溶媒、例えばメ
タノール、エタノール、アセトン、クロロホル
ム、ベンゼンなどに溶解し、これに非イオン界面
活性剤を混合後、有機溶媒を除去すればよい。 非イオン界面活性剤が固体の場合には、それを
加熱熔融後上記有機溶媒に溶かしたマクロテトロ
ライド系抗生物質と混合し、その後溶媒を除去
し、粉末とすればよい。又、賦形剤を使用する場
合は、マクロテトロライド系抗生物質及び、非イ
オン界面活性剤を賦形剤に別々に混合してもよい
が、上記混合物に賦形剤を添加して均一に混合す
る方が非イオン界面活性剤の使用量が少なくてす
み好ましい。 本発明の製剤中のマクロテトロライド系抗生物
質の濃度はその組成により異なるので一概にはい
えないが、製剤全体に対して0.0001%(以下特に
断わらない限り%は重量%を示す。)以上、好ま
しくは0.0005〜50%であり、例えばマクロテトロ
ライド系抗生物質、非イオン系界面活性剤及び賦
形剤からなる製剤の場合には0.1〜40%が好まし
く、マクロテトロライド系抗生物質及び非イオン
界面活性剤を含む飼料組成物の場合には0.0001%
〜0.1%、好ましくは0.0005〜0.05%である。 本発明の製剤を含む好ましい組成物を示すとマ
クロテトロライド系抗生物質0.0005〜40%、非イ
オン界面活性剤0.0005〜95%、経済的には0.001
〜60%及び残部は賦形剤及び/又は飼料からな
り、かつマクロテトロライド系抗生物質1重量部
に対し、非イオン界面活性剤が1〜1000重量部好
ましくは1〜200重量部の範囲にある組成物であ
る。この組成物は必要に応じて、更に一般に使用
される製剤用の助剤や飼料添加物を含んでもよ
い。 以上のようにして製造された本発明の製剤を家
畜及び家禽に経口的に連続的に投与することによ
り、マクロテトロライド系抗生物質が、それ単独
で投与する場合より有効に作用し、成長促進、飼
料効率の向上、疾病の予防及び治療などの効果が
充分発揮される。 本発明の製剤を投与する家畜・家禽は特に制限
はないが、実用的観点からすると牛、豚、鶏など
が好ましい。 又、その投与量は有効成分であるマクロテトロ
ライド系抗生物質として0.025mg/Kg/日以上、
好ましくは0.125〜12.5mg/Kg/日がよい。又、
その投与形態としては製剤をそのまま、又、マク
ロテトロライド系抗生物質と非イオン界面活性剤
からなる製剤又はそれと賦形剤とからなる製剤の
場合には散剤、錠剤、顆粒としてこれらを飼料や
飲水に混合して投与してもよい。 次に本発明の製剤がすぐれた効果をもつもので
あることを実施例により示す。 実験例 1 豚赤痢の感染防禦試験 (1) 試料の調製 ポリナクチン(成分割合はジナクチン:トリ
ナクチン:テトラナクチン=1:2:7)1重
量部をアセトン20重量部に溶解し、次いでその
溶液に非イオン界面活性剤10重量部を添加して
均一に混合溶解し、次いでこの溶液に脱脂米糠
89重量部を添加、均一に混合した後アセトンを
揮散させて粉末状の混合物としたものを表1に
示す基礎飼料にポリナクチン濃度0.003%にな
るように添加して得られた本発明組成物(C〜
I)の7点を試料とした。又、飼料単独(A)、ポ
リナクチンのみを0.003%添加した飼料(B)を対
照飼料とした。
The present invention is an antibacterial product for livestock and poultry containing a macrotetrolide antibiotic and a nonionic surfactant.
This invention relates to antiprotozoal agents and growth promoters. In recent years, macrotetrolide antibiotics have been used in livestock and
It has been found to be effective in promoting the growth of poultry, improving feed efficiency, and preventing and treating diseases, and its practical application is expected. However, the in-
There is a problem that the effect in vivo and the effect in in-vivo do not necessarily match, and the in-vivo effect has not been sufficiently discovered, and therefore the dosage must be increased. Therefore, the present inventors conducted various studies in order to ensure that the effects of macrotetrolide antibiotics can be fully demonstrated in-vivo.
By orally administering a composition containing a macrotetrolide antibiotic and a nonionic surfactant to livestock and poultry, its effects are fully exhibited,
It has been found that even if the dose is reduced, the growth promoting effect etc. can be sufficiently expressed. The present invention was completed based on the above findings. Examples of macrotetrolide antibiotics used in the present invention include nonactin, monactin, dinactin, trinactin, and tetranactin. These may be used in combination. Examples of nonionic surfactants include glycerin fatty acid ester, sucrose fatty acid ester, propylene glycol fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil derivative, etc. However, polyoxyethylene-based nonionic surfactants such as polyoxyethylene fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and polyoxyethylene hydrogenated castor oil derivatives are preferred. These may be used in combination. The ratio of the macrotetrolide antibiotic to the nonionic surfactant is 1 part by weight of the former to 1 part by weight or more of the latter, preferably 1 to 1000 parts by weight, and more preferably 1 to 100 parts by weight. The preparation of the present invention is not particularly limited as long as it contains a macrotetrolide antibiotic and a nonionic surfactant; Examples include preparations in which the above-mentioned agents are mixed together, and feeds containing the above-mentioned two agents. Examples of excipients include coarse wheat flour, wheat soot flour,
Examples include coarse soybean powder, soybean oil cake, cornstarch, cornmeal, defatted rice bran, wheat bran, sweet potato starch, lactose, yeast, fats and oils, calcium carbonate, talc, wood powder, carillon, chalk diatomaceous earth, water, physiological saline, etc. . The feed may be any commercially available feed for livestock and poultry, such as grains such as corn and milo, edible oil meal such as soybean meal, bran such as bran and rice bran, corn gluten meal, starch meal, soybean oil meal, etc. Manufactured lees such as molasses, meat and bone meal,
It is made by mixing feed ingredients such as fish meal, whey, skim milk powder, blood meal, feather meal, animal substances such as animal fats and oils in appropriate proportions, or by adding feed additives such as minerals, vitamins, and amino acids. It can also be feed. To produce the formulation of the present invention, a macrotetrolide antibiotic is dissolved in a volatile organic solvent such as methanol, ethanol, acetone, chloroform, benzene, etc., and a nonionic surfactant is mixed therein. Just remove it. When the nonionic surfactant is solid, it may be heated and melted, then mixed with the macrotetrolide antibiotic dissolved in the above-mentioned organic solvent, and then the solvent may be removed to form a powder. In addition, when using an excipient, the macrotetrolide antibiotic and the nonionic surfactant may be mixed separately with the excipient, but the excipient may be added to the above mixture to ensure uniformity. Mixing is preferable because the amount of nonionic surfactant used can be reduced. The concentration of the macrotetrolide antibiotic in the preparation of the present invention varies depending on its composition, so it cannot be stated unconditionally, but it is 0.0001% (hereinafter, % indicates weight % unless otherwise specified) or more based on the entire preparation, It is preferably 0.0005 to 50%, for example, in the case of a formulation consisting of a macrotetrolide antibiotic, a nonionic surfactant, and an excipient, 0.1 to 40% is preferable; 0.0001% for feed compositions containing surfactants
~0.1%, preferably 0.0005-0.05%. A preferred composition containing the preparation of the present invention includes 0.0005 to 40% macrotetrolide antibiotic, 0.0005 to 95% nonionic surfactant, and 0.001% economically.
~60% and the remainder consists of excipients and/or feed, and the nonionic surfactant is in the range of 1 to 1000 parts by weight, preferably 1 to 200 parts by weight, per 1 part by weight of the macrotetrolide antibiotic. It is a certain composition. This composition may further contain commonly used formulation auxiliaries and feed additives, if necessary. By continuously orally administering the preparation of the present invention produced as described above to livestock and poultry, the macrotetrolide antibiotic acts more effectively than when administered alone, promoting growth. , the effects of improving feed efficiency, preventing and treating diseases, etc. are fully demonstrated. There are no particular restrictions on the livestock/poultry to which the preparation of the present invention is administered, but from a practical standpoint, cows, pigs, chickens, etc. are preferred. In addition, the dosage is 0.025 mg/Kg/day or more as the active ingredient macrotetrolide antibiotic,
Preferably 0.125 to 12.5 mg/Kg/day. or,
The dosage form is the preparation as it is, or in the case of a preparation consisting of a macrotetrolide antibiotic and a nonionic surfactant, or a preparation consisting of it and an excipient, it can be administered as a powder, tablet, or granule in feed or drinking water. It may also be administered by mixing with Next, examples show that the formulation of the present invention has excellent effects. Experimental example 1 Infection prevention test for swine dysentery (1) Sample preparation Dissolve 1 part by weight of polynactin (component ratio: dinactin: trinactin: tetranactin = 1:2:7) in 20 parts by weight of acetone, and then add nonionic to the solution. Add 10 parts by weight of surfactant, mix and dissolve uniformly, then add defatted rice bran to this solution.
The composition of the present invention obtained by adding 89 parts by weight, uniformly mixing, and volatilizing the acetone to form a powder mixture was added to the basal feed shown in Table 1 so that the polynactin concentration was 0.003% ( C~
Seven points of I) were used as samples. In addition, feed alone (A) and feed containing only 0.003% polynactin (B) were used as control feeds.

【表】【table】

【表】 (2) 試験方法 体重約12Kgの子豚(LWD種)を1群当り5
頭(去勢雄)用い、各試料を自由摂取させ、試
料の摂取開始後3日目に、トレポネーマ・ハイ
オデイセンテリアの純粋培養寒天を1頭当り10
枚経口投与し人工感染させた。人工感染後21日
間糞便の状態を観察した。 (3) 試験結果 結果を表2に示す。
[Table] (2) Test method Five piglets (LWD breed) weighing approximately 12 kg were tested per group.
Using a castrated male head, each animal was allowed to take in each sample ad libitum, and on the 3rd day after the start of ingestion of the sample, 10 pieces of pure culture agar of Treponema hyodeisenteriae were added to each animal.
Artificial infection was caused by oral administration. The state of feces was observed for 21 days after artificial infection. (3) Test results The results are shown in Table 2.

【表】【table】

【表】 注2) 粘血便からはすべてトレポネーマハイ
オデイセンテリアが検出され、粘血便は豚赤
痢によるものであることを確認した。 表2から明らかなように本発明の試料C〜Iは
対照試料A,Bに比し、粘血便の発生例が少なく
又発生時期も遅くなり、さらに試験終了時には全
例消失した。特にポリオキシエチレン系界面活性
剤を使用した試料C〜Fでは粘血便の発生例がな
く、豚赤痢の予防効果が十分達成されていること
がわかる。 実験例 2 鶏によるコクシジウムの感染防禦試験 (1) 試料の調製 ポリナクチン(成分割合はジナクチン:トリ
ナクチン:テトラナクチン=1:4:5)1重
量部をアセトン20重量部に溶解し、次いでその
溶液に非イオン界面活性剤20重量部を添加して
均一に混合溶解し、次いでこの溶液にコーンス
ターチ79重量部を添加、均一に混合した後アセ
トンを揮散させて粉末状の混合物としたものを
表3に示す基礎飼料にポリナクチン濃度が
0.002%になるように添加した本発明組成物C
〜Hの6点を試料とした。又、飼料単独(A)、ポ
リナクチンのみを0.002%添加した飼料(B)を対
照試料とした。
[Table] Note 2) Treponema hyodeisenteriae was detected in all mucus and bloody stools, confirming that the mucus and bloody stools were caused by swine dysentery. As is clear from Table 2, samples C to I of the present invention had fewer instances of mucus and bloody stool than control samples A and B, and the occurrence time was delayed, and furthermore, all cases had disappeared by the end of the test. In particular, samples C to F in which polyoxyethylene surfactants were used did not have mucus and bloody stools, indicating that the preventive effect on swine dysentery was sufficiently achieved. Experimental Example 2 Coccidia Infection Prevention Test by Chickens (1) Sample Preparation 1 part by weight of polynactin (component ratio: dinactin: trinactin: tetranactin = 1:4:5) was dissolved in 20 parts by weight of acetone, and then the solution was 20 parts by weight of ionic surfactant was added and mixed and dissolved uniformly, then 79 parts by weight of cornstarch was added to this solution, and after uniformly mixing, acetone was volatilized to form a powder mixture, which is shown in Table 3. Polynactin concentration in basal feed
Composition C of the present invention added to 0.002%
Six points from ~H were used as samples. In addition, feed alone (A) and feed containing only 0.002% polynactin (B) were used as control samples.

【表】 (2) 試験方法 ブロイラー(アーバーエーカ種)の雌ビナを
1群当り5羽用いた。ヒナを初日令から5日間
薬物を含まない基礎飼料で飼育した後、6日令
より各試料を与え始めた。そして8日令にアイ
メリカテネラのオーシストを1羽当り、2×
104個経口投与し、人工感染させた。オーシス
ト投与後8日目にヒナを剖検し、盲腸の病変程
度を観察し、コクシジウム感染の程度を判断し
た。 盲腸病変は次の5段階に分けて判定規準とし
た。 −……盲腸は全く正常 +……盲腸の形は正常。内容物はやゝ流動性を
帯び色も黄色がかる。盲腸粘膜は部分的に
軽度の腫脹があり白つぽくなる。 ……盲腸の形はほゞ正常、粘膜の腫脹は全面
にみられる。内容に出血はなく、粘液は黄
色をおび褪色している。粘膜内には少数の
白色点状壊死巣や、出血斑がみられる。 ……盲腸の萎縮変形は明瞭で直腸よりもやや
長い程度となる。正常な内容物は全くなく
凝血又は灰白色チーズ状の変性物が充満し
ていることが多い。 盲腸壁の肥厚は顕著でもろくなり、点状出
血斑がまだ残つていることもある。病変は
盲腸基部にまで達するが直腸にまで達しな
い。 〓……盲腸の萎縮、変形は顕著、一般にソーセ
ージ状を呈し、その長さは直腸と同じか、
又は短かくなつている。 病変は直腸の1/3〜1/4位の所にまで達す
る。その他はと同じである。 (3) 試験結果 試験結果を表4に示す。
[Table] (2) Test method Five female broiler chickens (Arbor Acre species) were used per group. After the chicks were raised on a drug-free basal diet for 5 days from the first day of age, feeding of each sample was started from the 6th day of age. Then, at 8 days old, oocysts of Eimericatenella were added to each bird, 2×
104 were orally administered to cause artificial infection. On the 8th day after administration of the oocysts, the chicks were necropsied, the degree of lesions in the cecum was observed, and the degree of coccidia infection was determined. Cecal lesions were classified into the following five grades as criteria for evaluation. −……The cecum is completely normal. +……The shape of the cecum is normal. The contents are slightly fluid and yellowish in color. The cecal mucosa is slightly swollen and whitish. ...The shape of the cecum is almost normal, and swelling of the mucous membrane is visible all over. There is no bleeding in the contents, and the mucus is yellow and discolored. A small number of white punctate necrotic foci and hemorrhagic spots are seen within the mucosa. ...The atrophic deformity of the cecum is clear and it is slightly longer than the rectum. It is often devoid of any normal contents and filled with blood clots or off-white cheese-like degeneration. The cecal wall becomes noticeably thickened and brittle, and petechiae may still remain. The lesions extend to the base of the cecum but not to the rectum. 〓...The atrophy and deformation of the cecum are noticeable, generally sausage-shaped, and its length may be the same as that of the rectum.
Or it's getting shorter. The lesion extends to 1/3 to 1/4 of the rectum. Others are the same. (3) Test results The test results are shown in Table 4.

【表】 表4から明らかなように本発明の試料C〜Hは
対照飼料A,Bよりも抗コクシジウム効果がすぐ
れ、特にポリオキシエチレン系界面活性剤を使用
した試料C〜Eの抗コハクシジウム効果がすぐれ
ていた。 実験例 3 反芻家畜による発育促進試験 (1) 飼料の調製 ポリナクチン(成分割合はジナクチン:トリ
ナクチン:テトラナクチン=1:4:5)1重
量部をアセトン20重量部に溶解し、次いでその
溶液に非イオン界面活性剤20重量部を添加して
均一に混合溶解し、次いでこの溶液にフスマ69
重量部を添加、均一に混合した後アセトンを揮
散させて粉末状の混合物としたものを表5に示
す基礎飼料にポリナクチン濃度が0.005%にな
るように添加した本発明組成物C〜Fの4点を
試料とした。又、飼料単独(A)、ポリナクチンの
みを0.005%添加した飼料(B)を対照試料とした。
[Table] As is clear from Table 4, Samples C to H of the present invention have better anti-coccidial effects than Control Feeds A and B, and especially Samples C to E using polyoxyethylene surfactants have anti-coccidial effects. The effect was excellent. Experimental Example 3 Growth promotion test using ruminant livestock (1) Preparation of feed 1 part by weight of polynactin (component ratio: dinactin: trinactin: tetranactin = 1:4:5) was dissolved in 20 parts by weight of acetone, and then non-ionized was added to the solution. Add 20 parts by weight of surfactant and mix and dissolve uniformly, then add wheat bran 69 to this solution.
Parts by weight were added, uniformly mixed, and then the acetone was volatilized to form a powder mixture, which was added to the basal feed shown in Table 5 so that the polynactin concentration was 0.005%. A point was used as a sample. In addition, feed alone (A) and feed containing only 0.005% polynactin (B) were used as control samples.

【表】【table】

【表】 (2) 試験方法 体重約25Kgの緬羊(サフオーク種)を1群当
り4頭(♀2〓2)用い、試料を自由摂取さ
せ、試験開始時及び開始7週間後の体重を測定
し、又、その間の飼料摂取量も測定し、増体量
及び飼料要求率を求めた。 (3) 試験結果 結果を表6に示す。
[Table] (2) Test method Four sheep (Suffoak breed) weighing approximately 25 kg were used per group (♀2〓2), and the sheep were given free access to samples, and their body weights were measured at the start of the test and 7 weeks after the start of the test. In addition, feed intake during that period was also measured, and body weight gain and feed conversion ratio were determined. (3) Test results The results are shown in Table 6.

【表】【table】

【表】 表6から明らかなように本発明の試料C〜Fは
対照試料A,Bよりも増体量、飼料要求率ともに
すぐれ、発育促進増強効果及び飼料効率の改善が
認められた。 次に本発明の組成物の製造を実施例により説明
する。 実施例 1 ノナクチン1重量部をアセトン40重量部に溶解
し、次いでこの溶液にポリオキシエチレンソルビ
タンモノオレエート10重量部を添加して撹拌混合
し、均一の溶液状の組成物を得た。 実施例 2 実施例1で得られた液状組成物11重量部に脱脂
米糠89重量部に加えて混合し、次いでアセトンを
揮散させて粉末状の組成物を得た。 実施例 3 ポリナクチン(ジナクチン:トリナクチン:テ
トラナクチン=1:4:5)1重量部にアセトン
20重量部に溶解し、これを60℃に加熱熔融したポ
リオキシエチレン硬化とヒマシ油誘導体50重量部
に加えて撹拌混合し、均一の液状組成物とする。
次いでアセトンを揮散させた後冷却固化、次いで
粉砕して粉末状の組成物を得た。 実施例 4 実施例2で得た組成物5重量部を市販配合飼料
1000重量部に添加し、均一に混合して飼料組成物
を得た。
[Table] As is clear from Table 6, Samples C to F of the present invention were superior to Control Samples A and B in both body weight gain and feed conversion rate, and were found to have a growth promoting effect and an improvement in feed efficiency. Next, the production of the composition of the present invention will be explained with reference to Examples. Example 1 1 part by weight of nonactin was dissolved in 40 parts by weight of acetone, and then 10 parts by weight of polyoxyethylene sorbitan monooleate was added to this solution and mixed with stirring to obtain a uniform solution composition. Example 2 89 parts by weight of defatted rice bran were added to 11 parts by weight of the liquid composition obtained in Example 1 and mixed, and then acetone was evaporated to obtain a powdered composition. Example 3 Add acetone to 1 part by weight of polynactin (dinactin: trinactin: tetranactin = 1:4:5)
This is added to 50 parts by weight of cured polyoxyethylene and castor oil derivative heated and melted at 60°C, and stirred and mixed to form a uniform liquid composition.
Next, after volatilizing the acetone, the mixture was cooled and solidified, and then pulverized to obtain a powdery composition. Example 4 5 parts by weight of the composition obtained in Example 2 was added to commercially available mixed feed.
It was added to 1000 parts by weight and mixed uniformly to obtain a feed composition.

Claims (1)

【特許請求の範囲】 1 マクロテトロライド系抗生物質及び非イオン
界面活性剤を含有する家畜・家禽用抗菌・抗原虫
剤。 2 マクロテトロライド系抗生物質及び非イオン
界面活性剤を含有する家畜・家禽用生長促進剤。
[Claims] 1. An antibacterial/antiprotozoal agent for livestock and poultry containing a macrotetrolide antibiotic and a nonionic surfactant. 2. A growth promoter for livestock and poultry containing a macrotetrolide antibiotic and a nonionic surfactant.
JP56056933A 1981-04-17 1981-04-17 Orally administering composition for veterinary purposes Granted JPS57171919A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56056933A JPS57171919A (en) 1981-04-17 1981-04-17 Orally administering composition for veterinary purposes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56056933A JPS57171919A (en) 1981-04-17 1981-04-17 Orally administering composition for veterinary purposes

Publications (2)

Publication Number Publication Date
JPS57171919A JPS57171919A (en) 1982-10-22
JPH0214326B2 true JPH0214326B2 (en) 1990-04-06

Family

ID=13041312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56056933A Granted JPS57171919A (en) 1981-04-17 1981-04-17 Orally administering composition for veterinary purposes

Country Status (1)

Country Link
JP (1) JPS57171919A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260271A (en) * 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
JP6242655B2 (en) * 2013-10-29 2017-12-06 リンテック株式会社 Release method of functional substance, kit for releasing functional substance, and release composition

Also Published As

Publication number Publication date
JPS57171919A (en) 1982-10-22

Similar Documents

Publication Publication Date Title
EP1913943B1 (en) Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria
WO1991011111A1 (en) Method of raising meat producing animals to increase lean tissue development
JP2002538845A (en) Pet food for maintaining joint health and reducing the signs of arthritis in pet animals
JP2000515864A (en) Conjugated linoleic acid for maintaining or increasing bone mineral content
US20100105867A1 (en) Process for producing osteocalcin-containing extract
EP0941088B1 (en) Use of conjugated linoleic acid to enhance natural killer lymphocyte function
EP0460080B1 (en) Orally administerable calcium supplement for cattle
JP2005509602A (en) Composition for versatile dairy animals
US20060034781A1 (en) Peroral preparation for prevention or treatment of atopic dermatatis
JPH0214326B2 (en)
EP0342111B1 (en) Process for increasing the productivity of sows
JPH0556755A (en) Livestock feed additive and livestock feed
US20230040395A1 (en) Composition for suppressing obesity
US3916027A (en) Method of treating candida albicans infections in poultry
US20130136724A1 (en) Pig feed, and method for feeding same
HU182652B (en) Process for producing food-additives containing antibiotics
EP0237956B1 (en) Method of feeding ketoisocaproate to lactating domestic mammals
EP0424055B1 (en) Feedstuffs
US3943250A (en) Method and pharmaceutical preparations for treating and preventing physiological disturbances in vertebrates, caused by molds and yeasts
US3714361A (en) Certain hydroxamic acids as growth promoting agents
JPH06701B2 (en) Veterinary composition
EP0589105B1 (en) Improvement in livestock raising
JP2007116972A (en) Bone fracture preventive agent, and slipped tendon preventive agent
JP3212364B2 (en) New royal jelly formulation
JP2007104954A (en) Feed additive